Boston Scientific Corporation $BSX Shares Purchased by Evelyn Partners Investment Management LLP

Evelyn Partners Investment Management LLP boosted its position in Boston Scientific Corporation (NYSE:BSX) by 12.1% in the 4th quarter, Holdings Channel reports. The firm owned 141,888 shares of the medical equipment provider’s stock after acquiring an additional 15,353 shares during the quarter. Evelyn Partners Investment Management LLP’s holdings in Boston Scientific were worth $13,529,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Claret Asset Management Corp raised its stake in Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 102 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its stake in Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares during the last quarter. Outfitters Financial LLC raised its stake in Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after purchasing an additional 110 shares during the last quarter. Fayez Sarofim & Co raised its stake in Boston Scientific by 2.1% in the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock valued at $520,000 after purchasing an additional 111 shares during the last quarter. Finally, Natural Investments LLC raised its stake in Boston Scientific by 2.9% in the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after purchasing an additional 112 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

BSX stock opened at $46.83 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a market capitalization of $69.60 billion, a P/E ratio of 19.59, a P/E/G ratio of 0.88 and a beta of 0.56. The business’s 50-day moving average is $56.37 and its two-hundred day moving average is $74.95. Boston Scientific Corporation has a 1 year low of $45.99 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 9,800 shares of company stock valued at $554,012 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. Truist Financial reduced their price objective on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, June 4th. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Raymond James Financial restated an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. BTIG Research dropped their target price on Boston Scientific from $80.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, June 2nd. Finally, Bank of America dropped their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $85.08.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.